Literature DB >> 32162801

Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.

Mari Aso1, Yukihiro Toi1, Jun Sugisaka1, Tomoiki Aiba1, Sachiko Kawana1, Ryohei Saito1, Takahiro Ogasawara1, Kyoji Tsurumi1, Kana Ono1, Hisashi Shimizu1, Yutaka Domeki1, Keisuke Terayama1, Yosuke Kawashima1, Atsushi Nakamura1, Shinsuke Yamanda1, Yuichiro Kimura1, Yoshihiro Honda1, Shunichi Sugawara1.   

Abstract

BACKGROUND: Anti-programmed cell death 1 antibody is a standard therapy for advanced non-small cell lung cancer (NSCLC). However, immune-related adverse events (irAEs), such as skin reactions, are frequently observed. Although skin reactions are associated with clinical efficacy in melanoma, this association in advanced NSCLC and predictors of irAEs remain unclear. Accordingly, this study identified potential correlations of skin reactions with clinical efficacy and clinical predictors of development of skin reactions. SUBJECTS, MATERIALS, AND METHODS: We retrospectively surveyed patients with advanced NSCLC who received nivolumab or pembrolizumab monotherapy at Sendai Kousei Hospital (n = 155) during January 2016 to April 2018. Treatment efficacy was evaluated in patients with and without skin reactions, and associated predictive markers were determined. A 6-week landmark analysis was conducted to assess the clinical benefit of early skin reactions.
RESULTS: Skin reactions were observed in 51 patients with a median time to onset of 6.4 weeks. The overall response rate (ORR) was significantly higher in patients with skin reactions (57% vs. 19%, p < .001). Median progression-free survival (PFS) durations of 12.9 and 3.5 months and overall survival durations of not reached and 11.4 months were observed in patients with and without skin reactions, respectively. In the 6-week landmark analysis, the ORR was significantly higher in patients with skin reactions, and skin reactions were significantly associated with increased PFS. A multivariate analysis identified pre-existing rheumatoid factor (RF) as an independent predictor of skin reactions.
CONCLUSION: Skin reactions appeared beneficial in patients treated with nivolumab/pembrolizumab for advanced NSCLC and could be predicted by pre-existing RF. Further large-scale validations studies are warranted. IMPLICATIONS FOR PRACTICE: This single-institutional medical record review that included 155 patients with advanced non-small cell lung cancer who were treated with nivolumab or pembrolizumab monotherapy revealed that overall response rate and progression-free survival were significantly better in patients with skin reactions. Pre-existing rheumatoid factor was an independent predictor of skin reactions. © AlphaMed Press 2019.

Entities:  

Keywords:  Immune-related adverse events; Immunotherapy; Lung cancer; Programmed cell death 1; Rheumatoid factor; Skin reaction

Mesh：

Substances：

Year:  2019        PMID： 32162801      PMCID： PMC7066688          DOI： 10.1634/theoncologist.2019-0550

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  36 in total

1.  The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut.

Authors:  Shimpei Kawamoto; Thinh H Tran; Mikako Maruya; Keiichiro Suzuki; Yasuko Doi; Yumi Tsutsui; Lucia M Kato; Sidonia Fagarasan
Journal:  Science       Date:  2012-04-27       Impact factor: 47.728

2.  PD-1 is a novel regulator of human B-cell activation.

Authors:  Marie-Laure Thibult; Emilie Mamessier; Julie Gertner-Dardenne; Sonia Pastor; Sylvaine Just-Landi; Luc Xerri; Bruno Chetaille; Daniel Olive
Journal:  Int Immunol       Date:  2012-10-18       Impact factor: 4.823

3.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

4.  A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.

Authors:  A Lisberg; A Cummings; J W Goldman; K Bornazyan; N Reese; T Wang; P Coluzzi; B Ledezma; M Mendenhall; J Hunt; B Wolf; B Jones; J Madrigal; J Horton; M Spiegel; J Carroll; J Gukasyan; T Williams; L Sauer; C Wells; A Hardy; P Linares; C Lim; L Ma; C Adame; Edward B Garon
Journal:  J Thorac Oncol       Date:  2018-06-01       Impact factor: 15.609

5.  Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.

Authors:  Omar Hasan Ali; Stefan Diem; Eva Markert; Wolfram Jochum; Katrin Kerl; Lars E French; Daniel E Speiser; Martin Früh; Lukas Flatz
Journal:  Oncoimmunology       Date:  2016-09-19       Impact factor: 8.110

6.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

Authors:  H Nishimura; M Nose; H Hiai; N Minato; T Honjo
Journal:  Immunity       Date:  1999-08       Impact factor: 31.745

7.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

8.  Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.

Authors:  Martina Sanlorenzo; Igor Vujic; Adil Daud; Alain Algazi; Matthew Gubens; Sara Alcántara Luna; Kevin Lin; Pietro Quaglino; Klemens Rappersberger; Susana Ortiz-Urda
Journal:  JAMA Dermatol       Date:  2015-11       Impact factor: 10.282

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

10.  Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.

Authors:  Yukihiro Toi; Shunichi Sugawara; Yosuke Kawashima; Tomoiki Aiba; Sachiko Kawana; Ryohei Saito; Kyoji Tsurumi; Kana Suzuki; Hisashi Shimizu; Jun Sugisaka; Hirotaka Ono; Yutaka Domeki; Keisuke Terayama; Atsushi Nakamura; Shinsuke Yamanda; Yuichiro Kimura; Yoshihiro Honda
Journal:  Oncologist       Date:  2018-06-22
View more
  18 in total

1.  Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care.

Authors:  Robert D Schouten; Lucie Egberink; Mirte Muller; Cornedine J De Gooijer; Erik van Werkhoven; Michel M van den Heuvel; Paul Baas
Journal:  Transl Lung Cancer Res       Date:  2020-10

2.  Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy.

Authors:  Feliciano Barrón; Roberto Sánchez; Marisol Arroyo-Hernández; Carolina Blanco; Zyanya L Zatarain-Barrón; Rodrigo Catalán; Maritza Ramos-Ramírez; Andrés F Cardona; Diana Flores-Estrada; Oscar Arrieta
Journal:  Front Oncol       Date:  2020-09-29       Impact factor: 6.244

3.  Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.

Authors:  Tsuyoshi Isawa; Yukihiro Toi; Shunichi Sugawara; Masataka Taguri; Shigeru Toyoda
Journal:  Oncologist       Date:  2022-05-06       Impact factor: 5.837

4.  Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.

Authors:  Hiroshi Matsuoka; Takahiro Hayashi; Karen Takigami; Kazuyoshi Imaizumi; Ryoichi Shiroki; Naoki Ohmiya; Kazumitsu Sugiura; Kenji Kawada; Akira Sawaki; Koutaro Maeda; Yousuke Ando; Ichiro Uyama
Journal:  BMC Cancer       Date:  2020-07-14       Impact factor: 4.430

Review 5.  The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients.

Authors:  Alessandro Allegra; Eleonora Di Salvo; Marco Casciaro; Caterina Musolino; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Biomedicines       Date:  2020-12-22

6.  Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study.

Authors:  Saeka Egami; Hitoshi Kawazoe; Hironobu Hashimoto; Ryuji Uozumi; Toko Arami; Naomi Sakiyama; Yuichiro Ohe; Hideo Nakada; Tohru Aomori; Shinnosuke Ikemura; Koichi Fukunaga; Masakazu Yamaguchi; Tomonori Nakamura
Journal:  J Cancer       Date:  2021-02-16       Impact factor: 4.207

7.  Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis.

Authors:  Donghui Wang; Cen Chen; Yanli Gu; Wanjun Lu; Ping Zhan; Hongbing Liu; Tangfeng Lv; Yong Song; Fang Zhang
Journal:  Front Oncol       Date:  2021-03-01       Impact factor: 6.244

8.  Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China.

Authors:  Xiaoling Chen; Jun Nie; Ling Dai; Weiheng Hu; Jie Zhang; Jindi Han; Xiangjuan Ma; Guangming Tian; Sen Han; Di Wu; Yang Wang; Jieran Long; Ziran Zhang; Jian Fang
Journal:  Front Oncol       Date:  2021-03-05       Impact factor: 6.244

9.  Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study.

Authors:  Kenji Morimoto; Tadaaki Yamada; Chieko Takumi; Yuri Ogura; Takayuki Takeda; Keisuke Onoi; Yusuke Chihara; Ryusuke Taniguchi; Takahiro Yamada; Osamu Hiranuma; Yoshie Morimoto; Masahiro Iwasaku; Yoshiko Kaneko; Junji Uchino; Koichi Takayama
Journal:  Front Oncol       Date:  2021-03-23       Impact factor: 6.244

10.  Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.

Authors:  Kana Ono; Hirotaka Ono; Yukihiro Toi; Jun Sugisaka; Mari Aso; Ryohei Saito; Sachiko Kawana; Tomoiki Aiba; Tetsuo Odaka; Suguru Matsuda; Shin Saito; Akane Narumi; Takahiro Ogasawara; Hisashi Shimizu; Yutaka Domeki; Keisuke Terayama; Yosuke Kawashima; Atsushi Nakamura; Shinsuke Yamanda; Yuichiro Kimura; Yoshihiro Honda; Shunichi Sugawara
Journal:  Cancer Med       Date:  2021-06-13       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.